USP <601>
USP <601> anchors performance quality tests for inhalation and nasal aerosols, sprays, and powders.
AccreditedStandards
Dose Uniformity OINDPUSP <601>USP <1601>ISO 20072
Standards for emitted dose, delivered dose uniformity, and OINDP device performance data.
Use this standards cluster when MDI, DPI, nebulizer, nasal, or aerosol device programs need dose data aligned with compendial, FDA, and design-verification expectations.
Standard roster
Individual standards in this cluster
USP <601>, USP <1601>, FDA MDI/DPI guidance, and ISO 20072 form the citation set; ARE Labs translates them into dose collection, actuation, recovery, assay, QA, and report controls.
USP <1601>
USP <1601> applies when nebulization products need characterization of delivered drug amount, delivery rate, and aerodynamic aerosol assessment.
AlignedFDA MDI/DPI Guidance
FDA MDI/DPI guidance connects dose uniformity with product development, device performance, analytical method control, and CMC documentation.
AlignedISO 20072
ISO 20072 addresses design verification requirements and test methods for hand-held aerosol drug delivery devices.
AlignedPurpose & when to use
Dose delivery and dose uniformity standards define how OINDP programs collect, recover, quantify, and document emitted or delivered dose data. This cluster helps teams determine when USP <601>, USP <1601>, FDA MDI/DPI guidance, and ISO 20072 should frame studies of inhalers, nebulizers, nasal products, or aerosol drug delivery devices:
- MDI and DPI programs use USP <601> and FDA guidance when delivered dose uniformity, actuation handling, and assay outputs need one package.
- Nebulizer programs use USP <1601> when delivered amount, delivery rate, operating conditions, and aerosol collection must share one protocol.
- Device design teams use ISO 20072 when hand-held aerosol drug delivery verification informs fixture choice and acceptance criteria.
- Investigations use USP <601> or FDA expectations to separate formulation, device handling, recovery, and analytical contributors to variability.
Use this cluster when the question is not simply whether the dose was measured, but whether the result can be traced through device setup, collection, recovery, assay, deviations, and final interpretation.
Applicable to
Built around OINDP dose decisions
The cluster applies when delivered dose, emitted dose, or dose uniformity depends on device operation, flow conditions, collection geometry, recovery, and quantitative assay records.
Standards in this group
What each citation controls
This page is a cluster, not an individual-standard page. USP chapters frame compendial dose and nebulizer characterization, FDA guidance frames MDI and DPI quality documentation, and ISO 20072 adds device design-verification context. The summaries below explain what each citation controls, how it affects ARE Labs study design, and what source was verified.
USP
AccreditedUSP <601>
Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders - Performance Quality Tests
USP <601> anchors performance quality tests for inhalation and nasal aerosols, sprays, and powders. On dose uniformity work, it informs dose collection, actuation sequence, recovery, assay readiness, variability reporting, and documentation of delivered dose uniformity.
USP official preview page verified 2026-05-17; public preview identifies the chapter and 2023 citation.
USP
AlignedUSP <1601>
Products for Nebulization - Characterization Tests
USP <1601> applies when nebulization products need characterization of delivered drug amount, delivery rate, and aerodynamic aerosol assessment. ARE Labs uses it to plan controlled nebulizer operation, collection timing, recovery strategy, and assay-ready delivered-dose records.
USP official preview page verified 2026-05-17; public preview identifies the chapter and 2021 citation.
FDA
AlignedFDA MDI/DPI Guidance
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - Quality Considerations
FDA MDI/DPI guidance connects dose uniformity with product development, device performance, analytical method control, and CMC documentation. ARE Labs uses it to align protocol choices, replicate handling, assay outputs, deviations, and report language for MDI and DPI programs.
FDA official guidance page verified 2026-05-17; page identifies April 2018 draft guidance, not for implementation.
ISO
AlignedISO 20072
Aerosol drug delivery device design verification - Requirements and test methods
ISO 20072 addresses design verification requirements and test methods for hand-held aerosol drug delivery devices. On this cluster, it provides device context for fixtures, instructions-for-use assumptions, functionality profiles, and risk-based acceptance criteria rather than drug product quality assessment.
ISO official standard page verified 2026-05-17; page lists ISO 20072:2009 as published and confirmed in 2025.
Accredited where held, aligned where followed
ARE Labs separates formal accreditation from standards alignment. USP <601> is treated as accredited where scope applies; USP <1601>, FDA MDI/DPI guidance, and ISO 20072 are followed as aligned protocol frameworks unless separate scope is confirmed.
- USP <601>AccreditedAccredited delivered-dose performance frame where scope applies.
- USP <1601>AlignedNebulizer characterization frame followed by protocol.
- FDA MDI/DPI GuidanceAlignedDraft quality guidance translated into study records.
- ISO 20072AlignedDevice design-verification context applied where relevant.
Operational chain
How ARE Labs turns the standards into a study
The standards define the reference frame; the executable method still depends on device type, formulation, collection geometry, assay, and regulatory objective. ARE Labs translates USP, FDA, and ISO expectations into controlled dose studies.
01
Configuration
Select the dose collection path
We map USP <601>, USP <1601>, FDA, or ISO 20072 context to collection fixture, flow condition, actuation sequence, and recovery strategy.
Protocol setup02
Operation
Control device use conditions
Device conditioning, priming, actuation timing, leak checks, flow verification, and sample handling are recorded against the selected USP or FDA frame.
Traceable run record03
Quantitation
Tie recovered dose to assay output
USP <601> and FDA-aligned work connects collection recovery, extraction timing, analytical readiness, replicate variability, and assay results.
Assay-linked data file04
Adaptation
Document product-specific choices
When ISO 20072 device context or OINDP geometry does not map directly to a compendial setup, ARE Labs records the rationale.
Rationale log05
Reporting
Connect results to the citation set
Reports tie emitted dose, delivered dose uniformity, variability, recovery, deviations, and limitations back to USP, FDA, and ISO expectations.
Review-ready reportData quality, QA/QC & documentation
A dose uniformity result is only as useful as the records behind it. ARE Labs connects USP, FDA, and ISO study requirements with traceable setup checks, collection controls, recovery records, assay outputs, raw data retention, deviation rationale, and QA review so each result can be reviewed.
Connect setup to citation
USP <601> and USP <1601> runs link device setup, collection fixture, operating condition, and recovery timing to the selected study frame.
Preserve run conditions
FDA MDI/DPI expectations make actuation handling, flow verification, sample recovery, and assay readiness part of the review trail.
Retain raw and reduced data
USP <601> dose files retain recovered mass, replicate variability, calculations, analytical sequence references, and calibration or verification records.
Document design assumptions
ISO 20072 use is recorded when device instructions, risk assessment, or functionality profile affects fixture setup or acceptance criteria.
Separate scope from alignment
ISO 17025 review language distinguishes accredited USP <601> work from aligned USP <1601>, FDA guidance, or ISO 20072 context.
Why ARE Labs
ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.
Reviewed byJamie Balarashti - Weston Schaper
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported
Common questions
These questions help inhalation, nasal, nebulizer, and aerosol-device teams determine whether dose uniformity work should follow USP <601>, USP <1601>, FDA MDI/DPI guidance, ISO 20072, or a blended protocol. The answers outline the practical decisions ARE Labs resolves before drafting the protocol, planning samples, and defining the report.
Q. Which citation applies first?
A. Begin with the dosage form and study objective. USP <601> often frames delivered dose testing for inhalation or nasal products, USP <1601> frames nebulizer characterization, FDA guidance defines quality documentation expectations for MDIs and DPIs, and ISO 20072 provides additional device verification context.
Q. Is ISO 20072 a drug quality test?
A. No. ISO 20072 is a device design-verification standard. It can guide fixture design, use conditions, and acceptance criteria, but it does not replace product-quality testing required under USP or FDA expectations.
Q. What does aligned mean here?
A. Aligned means that ARE Labs follows the applicable standard or guidance through the study protocol. It does not imply formal accreditation unless the citation is included in the laboratory's accredited scope.
Q. How are source gaps handled?
A. ARE Labs links only to official publisher or regulator pages. If an official public URL or effective date cannot be verified, the field remains unset and the gap is documented.
Q. What records does the report include?
A. Reports can document setup conditions, the collection fixture, actuation sequence, flow verification, recovery, assay outputs, replicate variability, deviations, raw data references, and QA review. The protocol defines the final report contents.
Related services & devices
Related services & devices
Service
Dose Uniformity & Emitted Dose
Primary service route for delivered dose, emitted dose, recovery, assay, and replicate variability studies.Read more ->ServiceParticle Size Distribution (PSD) Testing
Pairs APSD and particle-size evidence with dose uniformity for inhalation performance packages.Read more ->ServiceSpray Pattern & Plume Geometry
Adds spray-shape and plume evidence for nasal or aerosolized dose programs.Read more ->ServiceBreathing Simulation
Connects emitted or delivered dose to inhalation profiles and patient-use flow conditions.Read more ->ServiceFormulation Development Support
Supports formulation changes when dose uniformity, recovery, and assay behavior need comparison data.Read more ->DevicesMetered Dose Inhalers
Pressurized inhaler devices where actuation, priming, delivered dose, and APSD often converge.Read more ->DevicesDry Powder Inhalers
Flow-dependent powder inhalers where dose emission depends on device resistance and use conditions.Read more ->DevicesNebulizers
Jet, mesh, ultrasonic, and related systems tied to delivered amount and delivery rate.Read more ->DevicesNasal Drug Spray Devices
Nasal formats where delivered dose may sit beside plume and spray-pattern evidence.Read more ->DevicesOral Spray Devices
Aerosol or spray formats where collection geometry and assay recovery need product-specific controls.Read more ->Related clusters
Related standards clusters
Dose uniformity sits beside particle-size, nebulizer, spray-imaging, and breathing-profile questions. These related standards clusters help teams route from delivered-dose evidence into adjacent OINDP performance requirements.
Standards - Live